Deal snapshot: AbbVie joins peers Merck & Co., Roche and Pfizer with a TL1A-targeted antibody for potential therapy in inflammatory bowel disease, paying $150m up front.
Who: AbbVie/FutureGen
What: AbbVie has licensed global development and commercialization rights to a preclinical TL1A-targeting antibody for development in inflammatory bowel disease...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Deal Snapshot: Bayer will take over development of the asset once Kumquat completes a Phase Ia clinical trial, but the biotech firm may opt in to share US profits and losses.
Royalty deals are on track for another blowout year, but it’s not only because of a depressed biotech market. Large investment firms such as KKR are taking note.
SEC filings reveal that Merck was the sole bidder for Verona and its COPD drug Ohtuvayre, with the final $10bn deal wrapped up within a month.
Aurobindo is confident its planned Lannett acquisition will pass US FTC scrutiny after an attempt to acquire Sandoz assets was called off in 2020 post a delay in approval. The deal could widen Aurobindo’s US manufacturing presence at a time when its US Q1 revenue saw a year-on-year decline
Scrip looks at the therapies projected to lead global sales by 2030. These frontrunners not only reflect advances in innovation but also shifting priorities in chronic disease management.
Lupin is hoping moves like intellectual property transfer for some products to the US will help mitigate the tariff impact even as it counts on growth from planned launches of GLP-1s and biosimilars while riding high on tolvaptan launched in Q1.
In this week's episode: Trump ups pressure on MFN pricing; Pfizer says pharma working with Trump on direct sales; Sanofi says direct sales worth considering: Aurigene Oncology CEO on biotech valuations and more; and Novartis progresses pipeline-in-a-product assets.
